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Atrial fibrillation (AF) is associated with increased morbid-
ity and mortality, in part due to the risk of thromboembolic
disease, particularly stroke. Without preventive treatment,
each year approximately 1 in 20 patients (5%) with AF will
have a stroke and the risk of stroke is the same regardless of
whether patients have paroxysmal or sustained AF. Strokes
associated with AF are usually more severe, with increased
risk of morbidity, mortality and poor functional outcome.
One year mortality in AF relates stroke is about 50%, and
half of all strokes associated with AF are major and disabling.
Pharmacological primary prevention remains the best ap-
proach to reducing the burden of stroke and meta analisy-
ses showed that antiplatelet therapy reduces incidence of
stroke by about 22% , and warfarin by about 66-68%.
The risk of early recurrent stroke (new stroke of embolic ori-
gin in the first two weeks) is 0.1%-1.3% per day what is
higher than in stroke from other causes. CHADS score in
patients with stroke is two or more what means that patients
are at high risk, and anticoagulant medication is recom-
mended. However, current data do not support the routine
use of anticoagulation early in acute ischemic stroke. Sev-
eral randomized, controlled trials that used iv. heparinoids,
sc. LMWH, or sc. UFH early after ischemic stroke failed to
show a significant overall benefit of treatment over controls.
It is well known that warfarin anticoagulation is highly effi-
cacious for long-term secondary prevention in AF patients
but there is insuffitient data regarding the proper timing of
warfarin introduction.
IST-International Stroke Trial (19 435 stroke patients, 3 169
with AF), CAST-Chinese Acute Stroke Trial (21 106 stroke
patients, 1 411 with AF) and HAEST-The Heparin in Acute
Embolic Stroke Trial (449 AF patients with acute ischemic
stroke) showed that aspirin offers a safe and effective option
for preventing early recurrent stroke in the first week or two
after stroke onset. 
Cohrane corner tested 24 trials with 23 748 patients treated
with unfractionated heparin, LMWH, heparinoids, oral an-
ticoagulants, and thrombin inhibitors within 48 hours of
stroke onset and concluded that data do not support the use
of any of the currently available anticoagulants in acute is-
chemic stroke and that Aspirin is an effective antithrombotic
alternative to anticoagulation, which is safe in the acute
phase of ischemic stroke
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